Glypican-3-Targeted Alpha Particle Therapy for Hepatocellular Carcinoma

Glypican-3 (GPC3) is expressed in 75% of hepatocellular carcinoma (HCC), but not normal liver, making it a promising HCC therapeutic target. GC33 is a full-length humanized monoclonal IgG1 specific to GPC3 that can localize to HCC in vivo. GC33 alone failed to demonstrate therapeutic efficacy when e...

Descripción completa

Detalles Bibliográficos
Autores principales: Bell, Meghan M., Gutsche, Nicholas T., King, A. Paden, Baidoo, Kwamena E., Kelada, Olivia J., Choyke, Peter L., Escorcia, Freddy E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792624/
https://www.ncbi.nlm.nih.gov/pubmed/33374953
http://dx.doi.org/10.3390/molecules26010004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7792624/
https://www.ncbi.nlm.nih.gov/pubmed/33374953
http://dx.doi.org/10.3390/molecules26010004

Ejemplares similares